JP2022553832A5 - - Google Patents

Info

Publication number
JP2022553832A5
JP2022553832A5 JP2022525903A JP2022525903A JP2022553832A5 JP 2022553832 A5 JP2022553832 A5 JP 2022553832A5 JP 2022525903 A JP2022525903 A JP 2022525903A JP 2022525903 A JP2022525903 A JP 2022525903A JP 2022553832 A5 JP2022553832 A5 JP 2022553832A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
ethoxy
bipyridine
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525903A
Other languages
English (en)
Japanese (ja)
Other versions
JP7657792B2 (ja
JP2022553832A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/058202 external-priority patent/WO2021091788A1/en
Publication of JP2022553832A publication Critical patent/JP2022553832A/ja
Publication of JP2022553832A5 publication Critical patent/JP2022553832A5/ja
Priority to JP2025050448A priority Critical patent/JP2025109202A/ja
Application granted granted Critical
Publication of JP7657792B2 publication Critical patent/JP7657792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525903A 2019-11-07 2020-10-30 メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用 Active JP7657792B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025050448A JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962932306P 2019-11-07 2019-11-07
US62/932,306 2019-11-07
PCT/US2020/058202 WO2021091788A1 (en) 2019-11-07 2020-10-30 Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025050448A Division JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用

Publications (3)

Publication Number Publication Date
JP2022553832A JP2022553832A (ja) 2022-12-26
JP2022553832A5 true JP2022553832A5 (enExample) 2023-11-07
JP7657792B2 JP7657792B2 (ja) 2025-04-07

Family

ID=75849034

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525903A Active JP7657792B2 (ja) 2019-11-07 2020-10-30 メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用
JP2025050448A Pending JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025050448A Pending JP2025109202A (ja) 2019-11-07 2025-03-25 メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用

Country Status (4)

Country Link
US (1) US12479825B2 (enExample)
EP (1) EP4054583A4 (enExample)
JP (2) JP7657792B2 (enExample)
WO (1) WO2021091788A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7359783B2 (ja) 2018-06-05 2023-10-11 クリネティックス ファーマシューティカルズ,インク. メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用
JP7657792B2 (ja) 2019-11-07 2025-04-07 クリネティックス ファーマシューティカルズ,インク. メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用
PT4077307T (pt) * 2019-12-18 2025-06-03 Crinetics Pharmaceuticals Inc Antagonistas do recetor de subtipo 2 da melanocortina (mc2r) à base de piperidina gem-dissubstituída e suas utilizações
JP7651574B2 (ja) 2019-12-23 2025-03-26 クリネティックス ファーマシューティカルズ,インク. スピロ環式ピペリジンメラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用
IL305952A (en) 2021-03-19 2023-11-01 Crinetics Pharmaceuticals Inc Melanocortin subtype 2 receptor (MC2R) antagonist for disease treatment
US20230405157A1 (en) * 2022-05-10 2023-12-21 Radionetics Oncology, Inc. Melanocortin type 2 receptor (mc2r) targeted therapeutics and uses thereof
GB202302618D0 (en) 2023-02-23 2023-04-12 Omass Therapeutics Ltd MC2R modulator compounds
WO2024175928A1 (en) 2023-02-23 2024-08-29 Omass Therapeutics Limited Mc2r modulator compounds
GB202302629D0 (en) 2023-02-23 2023-04-12 Omass Therapeutics Ltd MC2R modulator compounds
EP4714953A1 (en) * 2023-05-16 2026-03-25 Scohia Pharma, Inc. Melanocortin 2-type receptor antagonist
WO2026047334A1 (en) 2024-08-28 2026-03-05 Omass Therapeutics Limited Mc2r modulator compounds
WO2026047337A1 (en) 2024-08-28 2026-03-05 Omass Therapeutics Limited Mc2r modulator compounds
GB202412595D0 (en) 2024-08-28 2024-10-09 Omass Therapeutics Ltd Mc2r modulator compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284956A (en) 1988-09-06 1994-02-08 Hoffmann-La Roche Inc. Liquid crystalline mixtures containing 2-(2-fluorophenyl) pyridines
JP2881750B2 (ja) * 1988-09-06 1999-04-12 エフ・ホフマン‐ラ ロシユ アーゲー 2‐(2‐フルオロフエニル)‐ピリジン
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
US6890940B2 (en) 2001-06-29 2005-05-10 Kowa Co., Ltd. Bis(2-aryl-5-pyridyl) derivatives
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
EP1465867A1 (en) 2001-10-09 2004-10-13 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
AR037429A1 (es) 2001-11-26 2004-11-10 Schering Corp Derivados de piperidina antagonistas de la mch, composiciones farmaceuticas, un proceso para su elaboracion y el uso de dichos derivados, solos o en combinacion, para la fabricacion de un medicamento para tratamiento de la obesidad y de trastornos del snc
AU2003216274A1 (en) 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
JP2005534632A (ja) 2002-05-10 2005-11-17 ニューロクライン バイオサイエンセズ, インコーポレイテッド メラノコルチンレセプターリガンドとしての置換ピペラジン
WO2004081643A1 (en) 2002-12-20 2004-09-23 Kaiser Aerospace & Electronics Corp. Lenslet array with polarization conversion
EP1460073A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators
UA85194C2 (ru) 2003-08-11 2009-01-12 Ф.Хоффманн-Ля Рош Аг Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1
ATE374610T1 (de) 2003-09-09 2007-10-15 Hoffmann La Roche 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050192286A1 (en) 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
AR053712A1 (es) 2005-04-18 2007-05-16 Neurogen Corp Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide)
US7652024B2 (en) 2005-10-18 2010-01-26 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
RU2303597C1 (ru) 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
EA019094B1 (ru) * 2008-08-22 2014-01-30 Новартис Аг Пирролопиримидины и их применение
WO2010026124A1 (en) 2008-09-02 2010-03-11 Novartis Ag Picolinamide derivatives as kinase inhibitors
BRPI0917693A2 (pt) * 2008-09-02 2016-05-17 Neurosearch As composto derivado de triazol, composição farmacêutica, e, uso de um derivado de triazol
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
SG10201403696UA (en) 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
US9281726B2 (en) 2011-05-31 2016-03-08 Linak A/S Actuator
FR3017867A1 (fr) 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
EP3199156A1 (de) 2016-02-01 2017-08-02 Heinrich-Heine-Universität Düsseldorf Verwendung von glycin-transporter-1-antagonisten als zentralnervöse analgetika
EP3480198B1 (en) 2016-06-30 2021-05-05 Riken Novel compound or pharmaceutically acceptable salt thereof
US11377436B2 (en) * 2017-07-12 2022-07-05 The Brigham And Women's Hospital, Inc. EAAT2 enhancing molecules
RU2020115596A (ru) * 2017-10-17 2021-11-18 Мерк Патент Гмбх ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ TBK/IKKε И ИХ ПРИМЕНЕНИЯ
JP7359783B2 (ja) 2018-06-05 2023-10-11 クリネティックス ファーマシューティカルズ,インク. メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用
JP7657792B2 (ja) 2019-11-07 2025-04-07 クリネティックス ファーマシューティカルズ,インク. メラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用
PT4077307T (pt) 2019-12-18 2025-06-03 Crinetics Pharmaceuticals Inc Antagonistas do recetor de subtipo 2 da melanocortina (mc2r) à base de piperidina gem-dissubstituída e suas utilizações
JP7651574B2 (ja) 2019-12-23 2025-03-26 クリネティックス ファーマシューティカルズ,インク. スピロ環式ピペリジンメラノコルチンサブタイプ-2受容体(mc2r)アンタゴニストおよびその使用
US11565011B2 (en) 2020-09-18 2023-01-31 Ncr Corporation Sterilizing media cassette
US20230405157A1 (en) 2022-05-10 2023-12-21 Radionetics Oncology, Inc. Melanocortin type 2 receptor (mc2r) targeted therapeutics and uses thereof

Similar Documents

Publication Publication Date Title
JP2007508346A5 (enExample)
RU2497813C2 (ru) 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение
JP2007531752A5 (enExample)
RU2497822C2 (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2022531801A5 (enExample)
JP2023523438A5 (enExample)
JP2015503529A5 (enExample)
RU2016108753A (ru) Ингибиторы ферментов
CA2476343A1 (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
JP2011518836A5 (enExample)
JP2010513444A5 (enExample)
JP2010502615A5 (enExample)
JP2017522346A5 (enExample)
RU2010146384A (ru) Пирролидиноновые активаторы глюкокиназы
JP2009536196A5 (enExample)
RU2005136368A (ru) Производные пиперазина и их применение для лечения неврологических и психиатрических заболеваний
JP2007523905A5 (enExample)
JP2006500369A5 (enExample)
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2006503081A5 (enExample)
JP2020526547A5 (enExample)
RU2015111133A (ru) Ингибиторы тирозинкиназы брутона
JP2014513122A5 (enExample)
RU2019122999A (ru) Новое соединение и его фармакологически приемлемая соль
JP2018520201A5 (enExample)